Skip to content

A clinical trial on Naruvili Chooranam in the management of Iraippu Noi ( Bronchial Asthma)

A PROSPECTIVE OPEN LABELLED ,SINGLE ARM,NON-RANDOMIZED SINGLE CENTRIC PHASE II CLINICAL EVALUATION OF NARUVILI CHOORANAM IN THE MANAGEMENT OF IRAIPPU NOI (BRONCHIAL ASTHMA)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052415
Enrollment
40
Registered
2023-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

Intervention1: NARUVILI CHOORANAM: 5 gram/twice a day(orally) with hotwater 45 days Intervention2: NARUVILI CHOORANAM: Dosage: 2.5g (bds) Adjuvant: Hot water Route: Oral Frequency: twice a day Durati

Sponsors

Government Siddha Medical college and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.More than 30 and less than 60 years 2.Patient with the symptoms of dry cough,recurrent attacks of dyspnoea,hoarseness of voice,tightness of the chest,profuse sweating and wheezing 3.History of allergens,climatic changes 4.Patients who are willing to take radiological investigations & provide blood for lab investigations

Exclusion criteria

Exclusion criteria: 1.Below 29 and above 60 years 2.Cardiac diseases 3.Chronic allergic bronchitis 4.Tuberculosis 4.COPD 5.Pregnancy and Lactating mothers 6.Status Asthmaticus 7.Systemic Hypertension 8.Autoimmune diseases 9.Drugs and chemicals

Design outcomes

Primary

MeasureTime frame
If during treatment or after treatment reduction of the following symptoms: 1.Tightness of the chest 2.Wheezing 3.Dyspnoea 4.Difficulty in both inspiration and ExpirationTimepoint: 45 days

Secondary

MeasureTime frame
1.Comparing the pre and post treatment of Peak Expiratory Flow rate 2.Comparing the following parameters before and after treatment. a. Other clinical symptoms 2. Eosinophil (%) and ESR 3.Asthma Grade level Grade 1:Intermittent Grade 2: Mild Persistent Grade 3: Moderate Persistent Grade 4: Severe PersistentTimepoint: 45 days

Countries

India

Contacts

Public ContactProf Dr A Manoharan MDs PhD

Government Siddha Medical College and Hospital,Palayamkottai

siddhadrgs21@gmail.com9443358271

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026